Latest Ratios: P/E Ratio 45.5x · EV/EBITDA 35.4x · ROE 11.0%. (2021–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $64M | $116M | $159M | $30M | $56M | $207M |
| Enterprise Value | $87M | $139M | $173M | $49M | $71M | $221M |
| P/E Ratio → | 45.51 | 80.00 | 34.86 | — | — | 88.00 |
| P/S Ratio | 1.04 | 1.87 | 3.03 | 0.80 | 1.49 | 7.02 |
| P/B Ratio | 3.75 | 6.59 | 10.62 | 15.63 | 9.83 | 27.73 |
| P/FCF | — | — | — | — | — | 463.03 |
| P/OCF | — | — | 80.50 | — | — | 89.17 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.24 | 3.30 | 1.32 | 1.91 | 7.50 |
| EV / EBITDA | 35.36 | 56.36 | 28.47 | — | — | 73.37 |
| EV / EBIT | 55.54 | 88.52 | 33.62 | — | — | 62.96 |
| EV / FCF | — | — | — | — | — | 494.56 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | 25.8% | 25.8% | 30.9% | 21.0% | 22.4% | 29.5% |
| Operating Margin | 2.5% | 2.5% | 9.8% | -9.5% | -6.1% | 8.7% |
| Net Profit Margin | 2.9% | 2.9% | 8.1% | -11.8% | -7.0% | 7.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | 11.0% | 11.0% | 50.3% | -116.3% | -40.0% | 31.1% |
| ROA | 3.6% | 3.6% | 10.2% | -13.2% | -8.5% | 8.2% |
| ROIC | 3.4% | 3.4% | 15.3% | -12.4% | -7.9% | 8.9% |
| ROCE | 5.2% | 5.2% | 24.7% | -19.2% | -11.1% | 12.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | 1.38 | 1.38 | 1.02 | 11.18 | 3.20 | 1.98 |
| Debt / EBITDA | 9.85 | 9.85 | 2.52 | — | — | 4.90 |
| Net Debt / Equity | — | 1.31 | 0.93 | 10.27 | 2.82 | 1.89 |
| Net Debt / EBITDA | 9.33 | 9.33 | 2.29 | — | — | 4.68 |
| Debt / FCF | — | — | — | — | — | 31.53 |
| Interest Coverage | 1.69 | 1.69 | 7.66 | -4.23 | -5.91 | 3.04 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 2.07 | 2.07 | 1.14 | 1.05 | 1.20 | 1.58 |
| Quick Ratio | 0.74 | 0.74 | 0.35 | 0.40 | 0.56 | 0.75 |
| Cash Ratio | 0.09 | 0.09 | 0.05 | 0.11 | 0.16 | 0.09 |
| Asset Turnover | — | 1.24 | 1.05 | 1.13 | 1.11 | 1.04 |
| Inventory Turnover | 2.49 | 2.49 | 1.78 | 2.94 | 3.28 | 3.41 |
| Days Sales Outstanding | — | 40.20 | 33.95 | 33.93 | 46.30 | 48.75 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | 2.2% | 1.3% | 2.9% | — | — | 1.1% |
| FCF Yield | — | — | — | — | — | 0.2% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $73M | $65M | $50M | $49M | $47M |
Liquidity and margin volatility
As reported in quarterly financial statements, Solesence's ROIC has fluctuated significantly, swinging from a peak of 8.5% in 2024Q3 to a negative 1.0% in 2026Q1, which underscores the company's persistent struggle to generate consistent, value-accretive returns on its specialized manufacturing asset base.
The erratic nature of ROIC suggests that the company's profitability is highly sensitive to manufacturing throughput and capacity utilization. Investors should monitor whether the firm can stabilize these returns as it scales, or if the capital-intensive nature of its nanomaterial production will continue to dilute shareholder value.
Based on the company's reported figures, the cash conversion cycle remains extended, reaching 172 days in 2026Q1, which reflects significant inefficiencies in inventory management and a reliance on slow-turning stock that ties up critical liquidity needed for ongoing operations.
The high days inventory outstanding (DIO) relative to peers suggests that Solesence may be over-producing or struggling to align its manufacturing output with actual customer demand. This inefficiency forces the company to carry a heavy working capital burden, further straining its already limited cash reserves.
According to recent SEC filings, the quick ratio has deteriorated to 0.70 as of 2026Q1, indicating that the company's liquid assets are insufficient to cover its immediate short-term obligations without relying on the liquidation of potentially slow-moving inventory.
This liquidity profile appears vulnerable, especially given the company's history of negative free cash flow and reliance on external financing. Any disruption in the timing of customer payments or a slowdown in sales could force the company to seek dilutive capital to maintain its operations.
Market participants frequently rely on the P/S ratio to value Solesence, yet this metric obscures the company's structural inability to convert top-line revenue into meaningful operating profit, as evidenced by the thin 2.53% operating margin reported in recent periods.
Using P/S ignores the high variable cost structure and the significant R&D burden inherent in the firm's CDMO-like business model. A more appropriate valuation framework would focus on EV/EBITDA or free cash flow yield to better capture the true economic reality of the company's manufacturing-heavy operations.
Includes 30+ ratios · 5 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SLSN stock.
Solesence, Inc. Common Stock's current P/E ratio is 45.5x. The historical average is 67.6x. This places it at the 33th percentile of its historical range.
Solesence, Inc. Common Stock's current EV/EBITDA is 35.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 52.7x.
Solesence, Inc. Common Stock's return on equity (ROE) is 11.0%. The historical average is -12.8%.
Based on historical data, Solesence, Inc. Common Stock is trading at a P/E of 45.5x. This is at the 33th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Solesence, Inc. Common Stock has 25.8% gross margin and 2.5% operating margin.
Solesence, Inc. Common Stock's Debt/EBITDA ratio is 9.9x, indicating high leverage. A ratio above 4x may signal elevated financial risk.